VK2735
InvestigationalAlso known as: Viking 2735
A dual GLP-1/GIP receptor agonist from Viking Therapeutics with both subcutaneous and oral formulations. Phase 2 VENTURE trial showed 14.7% weight loss at 13 weeks (SC) and 12.2% (oral). Phase 3 VANQUISH-1 enrollment completed with 4,650 patients.
Research Statistics
Dual GLP-1/GIP agonist (Viking Therapeutics) in Phase 2 for obesity; Phase 3 announced. Subcutaneous and oral formulations in development. US-led trials with international sites. GLP-1 and GIP receptor mechanisms are individually well-established; dual agonism rationale supported by tirzepatide's Phase 3 success.
Research Dossier
Overview
What is VK2735 and what does the research say?
Mechanism of Action
The mechanisms of VK2735 are based on its dual GLP-1/GIP receptor agonism, a well-characterized pharmacological approach validated by tirzepatide approval.
How It Works (Simplified)
VK2735 activates two complementary hormone pathways for enhanced metabolic effects:
Binds GLP-1 receptors in brain and gut, reducing appetite, slowing gastric emptying, and enhancing glucose-dependent insulin release.
Activates GIP receptors on fat cells and pancreas, amplifying metabolic effects and potentially improving adipose tissue function.
Combined activation produces greater weight loss than either pathway alone, as demonstrated by tirzepatide vs semaglutide comparisons.
VK2735 oral formulation achieves systemic absorption without food restrictions, unlike oral semaglutide which requires fasting.
Scientific Pathways
GLP-1 Receptor Pathway (Appetite & Glucose)
VK2735 → GLP-1R activation → Hypothalamus satiety → Reduced food intake
→ Pancreatic beta cells → Insulin secretion
→ Gastric emptying delay → Postprandial glucose controlGIP Receptor Pathway (Metabolic Enhancement)
VK2735 → GIPR activation → Adipose tissue → Enhanced lipid handling
→ Pancreatic beta cells → Amplified insulin responseKey Research: VENTURE Phase 2 (2024) demonstrated 14.7% weight loss at 13 weeks with no plateau, suggesting continued efficacy with longer treatment.
Important Limitations
- Phase 3 data (VANQUISH-1) not yet available; efficacy based on Phase 2
- Long-term safety beyond 13 weeks not established in published data
- NOT commercially available - investigational drug only
- Comparison to approved agents (tirzepatide, semaglutide) requires Phase 3 results
Evidence-Chained Benefits
Evidence-Chained Benefits
Research findings linked to mechanisms and clinical outcomes
What to Expect
Timeline based on observations from published studies. Individual responses may vary.
Initial dose titration phase. GI side effects (nausea, diarrhea) most common during this period but typically mild-moderate. Early appetite suppression begins.
Continued weight loss with dose escalation. VENTURE data showed progressive weight reduction without plateau through week 13.
Phase 2 endpoint. 14.7% weight loss achieved at highest SC dose. Weight loss curves still declining, suggesting further reduction possible with longer treatment.
Phase 3 duration. VANQUISH-1 will evaluate 78-week efficacy and safety. Maintenance dosing study exploring weekly, biweekly, and monthly regimens.
Research-Based Observations
This timeline reflects observations from published clinical and preclinical studies. Individual responses may vary significantly. This is not a guarantee of effects or a dosing schedule. Consult qualified healthcare providers for personalized guidance.
Quality Checklist
Visual indicators to help evaluate VK2735 product quality
Good Signs (4 indicators)
Warning Signs (3 indicators)
Bad Signs (3 indicators)
For Research Evaluation Only
These quality indicators are general guidelines based on typical peptide characteristics. Professional laboratory testing (HPLC, mass spectrometry) provides definitive quality verification. This checklist is for initial visual evaluation only.
Peptide Interactions
Known and theoretical interactions when combining VK2735 with other peptides. Based on published research and mechanistic considerations.
Tesamorelin
CompatibleDifferent mechanisms (GH-releasing vs incretin agonism). May have complementary effects on body composition. No interaction studies available.
BPC-157
CautionBoth affect GI function. VK2735 slows gastric emptying while BPC-157 is gastroprotective. Monitor GI symptoms if combined.
Tirzepatide
AvoidSame mechanism of action (dual GLP-1/GIP agonism). Concurrent use would be duplicative with increased risk of adverse effects. No clinical rationale for combination.
Semaglutide
AvoidOverlapping GLP-1 receptor agonism. Concurrent use would increase risk of GI adverse effects and hypoglycemia without additional benefit.
Research Note: Interaction data is based on published literature, mechanistic understanding, and theoretical considerations. Most peptide combinations lack direct clinical study. This information is for educational purposes only and does not constitute medical advice. Always consult qualified healthcare providers.
References
Key Studies Cited
Full reference list available on request. All citations link to PubMed for verification.
Methodology Note
This dossier synthesizes available evidence from peer-reviewed literature, regulatory documents, and clinical trial registries. Evidence strength ratings follow a modified GRADE approach.
For complete methodology details, see our Methodology page.
Important Disclaimer
This dossier is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before making health decisions.
Get Research Alerts
New dossiers and major study summaries delivered to your inbox. Evidence-graded, citation-backed research you can trust.
No spam. Unsubscribe anytime.
Compare VK2735
VK2735 Calculators
Related Peptides
5-Amino-1MQ
5-Amino-1-Methylquinolinium, NNMT Inhibitor
A small molecule NNMT inhibitor studied for metabolic effects in animal models. No human clinical trials have been conducted. Increases NAD+ levels in adipose tissue in preclinical studies.
Amycretin
NNC0487-0111, Oral Amycretin, Subcutaneous Amycretin
A novel single-molecule dual GLP-1/amylin receptor agonist developed by Novo Nordisk. Unlike CagriSema (a fixed-dose combination), amycretin is a unified peptide that activates both pathways. Phase 1 trials showed superior weight loss signals versus semaglutide, with both oral and subcutaneous formulations in development.
AOD-9604
Anti-Obesity Drug 9604, Tyr-hGH Fragment 177-191, hGH Fragment 176-191
A modified fragment of human growth hormone (amino acids 176-191 with N-terminal tyrosine) studied for fat loss. Clinical development discontinued after Phase 2b/3 trials failed to show efficacy in 536 subjects. Now prohibited by WADA and excluded from FDA compounding.
Cagrilintide
AM833, NN9838, ZP8396
A long-acting amylin analog developed by Novo Nordisk for weight management. Currently in Phase 3 trials as CagriSema (combination with semaglutide). Phase 2 data shows up to 22-25% weight loss when combined with semaglutide, potentially exceeding tirzepatide efficacy.
CagriSema
Cagrilintide-Semaglutide, NNC0174-0833
A fixed-dose combination of cagrilintide (amylin analog) and semaglutide (GLP-1 agonist) for chronic weight management. Phase 3 REDEFINE trials demonstrate 20-23% weight loss at 68 weeks. NDA submitted to FDA December 2025. First GLP-1/amylin combination therapy.
CT-388
RG-6912
A dual GLP-1/GIP receptor agonist acquired by Roche through the $2.7 billion Carmot Therapeutics acquisition in 2024. Phase 1b results showed 18.8% placebo-adjusted weight loss at 24 weeks, positioning it as a competitive obesity therapeutic with a mechanism similar to tirzepatide.